Systemic therapy approved to treat cutaneous lymphoma

摘要

Gloucester Pharmaceuticals announced November 5 that FDA approved the marketing of romidepsin, or Istodax, for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have already received at least one systemic therapy for the disease.rnPatients with localized CTCL, FDA said, receive topical treatment or phototherapy. But in cases when the disease spreads to the blood, lymph nodes, or internal organs, patients may receive chemotherapy, the agency said.